Browsing Tag
Eli Lilly and Company
178 posts
Lilly’s Phase 3 EMBER-3 trial results set to shake up breast cancer treatment landscape
Eli Lilly and Company (NYSE: LLY) announced it will present data from its Phase 3 EMBER-3 trial for…
Lilly’s $4.5bn Medicine Foundry aims to redefine how clinical trial drugs are made
Find out how Eli Lilly and Company’s $4.5bn Medicine Foundry aims to transform clinical trial manufacturing and accelerate next-generation therapies.
Eli Lilly’s once-weekly insulin efsitora alfa matches daily insulin for A1C reduction, boosts stock interest
Eli Lilly and Company (NYSE: LLY) announced results from its QWINT-5 phase 3 trial, demonstrating that its once-weekly…
Organon and Eli Lilly expand global reach of migraine treatment Emgality
Organon and Eli Lilly and Company have expanded their commercialization agreement for Emgality, a leading migraine treatment, into…
This diabetes breakthrough drug slashes risk by 94%—discover how tirzepatide is transforming obesity treatment
Eli Lilly and Company (NYSE: LLY) has released compelling results from the SURMOUNT-1 study, which highlights that tirzepatide…
Eli Lilly and OpenAI forge pioneering alliance to combat antimicrobial resistance
Eli Lilly and Company (NYSE: LLY) has entered into a partnership with OpenAI to harness generative AI for…
Lilly to expand Indiana facility with record $5.3bn investment to boost production of APIs
In a historic move for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has announced a staggering…
Akouos AK-OTOF yields positive results in hearing restoration Phase 1/2 study
In a significant advancement for medical science and hearing loss treatment, Akouos, Inc., a wholly owned subsidiary of…
Eli Lilly and Company completes $1.4bn acquisition of POINT Biopharma
Eli Lilly and Company (NYSE: LLY) has announced the successful completion of its $1.4 billion acquisition of POINT…
Eli Lilly and Company announces first Lilly Gateway Labs facility in San Diego for 2024
In a strategic move to strengthen its position in the life sciences sector, Eli Lilly and Company (NYSE:…